Articles By Estel Grace Masangkay

  1. Roche And Garvan Link In Epigenetics Tech Development 8/21/2014
    Roche announced that it has entered into collaboration with the Garvan Institute of Medical Research to co-develop new technologies for targeted epigenomics analysis using DNA sequencing techniques.
  2. Novartis Licenses Drug Candidates To TB Alliance 8/21/2014
    Novartis announced that it has signed into an exclusive global licensing agreement with Global Alliance for TB Drug Development (TB Alliance) to provide anti-tuberculosis compounds discovered at the Novartis Institutes for Tropical Diseases (NITD).
  3. Bone Marrow Drug Reverses Alopecia, Restores Hair Growth 8/21/2014
    Researchers from Columbia University Medical Centre reported that the bone marrow drug ruxolitinib, marketed as Jakavi by Novartis, completely reversed baldness in three patients with alopecia.
  4. Janssen And NICE Urged To Talk After Zytiga Rejection 8/20/2014

    Last week, the UK’s drug approval body the National Institute for Health and Care Excellence (NICE) issued its draft guidance which does not recommend Johnson & Johnson unit Janssen’s prostate cancer drug Zytiga (abiraterone).

  5. Sanofi Licenses 2 Respiratory Drugs To ZAI Lab 8/19/2014

    Shanghai-based drug development firm ZAI Lab announced that it has signed into a global licensing agreement with Sanofi to obtain rights to two novel compounds which are potential treatments for chronic respiratory diseases.

  6. Mallinckrodt Completes Questcor Pharma Acquisition For $5.8 Billion 8/19/2014
    Global specialty pharmaceutical company Mallinckrodt announced that it has accomplished the acquisition of Questcor Pharmaceuticals for an estimated $5.8 billion in cash and stock transaction.
  7. TNI Biotech And Hubei Qianjiang Expand Partnership 8/18/2014

    TNI Biotech announced that it has expanded its collaboration with Hubei Qianjiang Pharmaceutical with the signing of a supplemental agreement focusing on its immunotherapy IRT-101 (MENK).

  8. Pfizer Reports Top-Line Results From Lyrica China Study 8/15/2014

    Pfizer posted top-line results from its two studies in China investigating Lyrica (pregabalin) in patients with postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (pDPN).

  9. Health Canada Approves GSK's Action Plan On Quebec Plant 8/14/2014
    Health Canada has given GlaxoSmithKline the green light to begin its plan to address contamination issues at its flu vaccine production plant at Ste. Foy in Quebec, Canada.
  10. Evidence Of Osteoporosis Drugs' Breast Cancer Prevention 'Misleading' 8/14/2014

    A new analysis of clinical trial data by a researcher team at the University of California, San Francisco suggests that earlier evidence linking use of osteoporosis drugs and successful breast cancer prevention was misleading.